| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
4'-Hydroxyflavanone targets SREBP maturation and lipid synthesis pathways. SREBPs are transcription factors that regulate the expression of genes involved in cholesterol and fatty acid biosynthesis. By inhibiting SREBP maturation, 4'-Hydroxyflavanone reduces the expression of lipogenic genes and decreases lipid accumulation in cells. The compound also has antioxidant, anti-inflammatory, and anticancer properties. Its biological effects are mediated through free radical scavenging, inhibition of inflammatory enzymes, and modulation of cellular signaling pathways. This makes it a potential research tool for metabolic and inflammatory diseases.
|
|---|---|
| ln Vitro |
In vitro, 4'-Hydroxyflavanone demonstrates SREBP maturation inhibition and suppression of lipid synthesis. The compound reduces lipid accumulation in hepatocytes and other cell types by decreasing the expression of lipogenic genes such as FASN and SCD1. It also exhibits antioxidant activity by scavenging free radicals and anti-inflammatory effects by inhibiting enzymes involved in inflammation. Anticancer properties have been reported, including inhibition of cancer cell proliferation. The compound is used as a research tool for studying hepatic steatosis, dyslipidemia, and related metabolic disorders.
|
| ln Vivo |
In vivo, 4'-Hydroxyflavanone has potential research value for the treatment of hepatic steatosis and dyslipidemia. As an inhibitor of SREBP maturation and lipid synthesis, the compound may reduce hepatic lipid accumulation and improve lipid profiles in animal models of metabolic disease. Its antioxidant and anti-inflammatory properties may also contribute to beneficial effects in metabolic and inflammatory conditions. Further in vivo studies are needed to fully characterize the compound's efficacy and safety profile.
|
| Enzyme Assay |
In vitro enzyme assays for 4'-Hydroxyflavanone involve measuring SREBP maturation and lipogenic enzyme activity. The standard protocol includes treating hepatocytes or other cell types with varying concentrations of 4'-Hydroxyflavanone (0.1-100 µM). SREBP maturation is assessed by western blot analysis of nuclear and cytoplasmic fractions to detect the cleaved, active form of SREBP. Lipogenic gene expression (e.g., FASN, SCD1, ACC) is measured by qPCR. Lipid accumulation is quantified by Oil Red O staining or lipid extraction. Antioxidant activity is assessed by DPPH or ABTS radical scavenging assays.
|
| Cell Assay |
Cell-based assays for 4'-Hydroxyflavanone are conducted in hepatocytes (e.g., HepG2, primary hepatocytes) or other cell lines. Cells are treated with 4'-Hydroxyflavanone at concentrations ranging from 0.1-100 µM for 24-72 hours. Lipid accumulation is assessed by Oil Red O staining and quantification. Cellular triglyceride and cholesterol levels are measured by enzymatic assays. SREBP maturation and expression of lipogenic genes are analyzed by western blot and qPCR. Inflammatory cytokine production is measured by ELISA. Cell viability is assessed to confirm lack of cytotoxicity.
|
| Animal Protocol |
In vivo animal experiments for 4'-Hydroxyflavanone would typically use rodent models of metabolic disease such as high-fat diet-induced obesity or genetic models of dyslipidemia. Animals would be administered 4'-Hydroxyflavanone via oral gavage or intraperitoneal injection. Endpoints would include body weight, food intake, liver weight, hepatic lipid content, serum lipid profiles (triglycerides, cholesterol, LDL, HDL), glucose tolerance, and insulin sensitivity. Liver histology would be performed to assess steatosis. Gene expression analysis would evaluate the effects on SREBP target genes.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for 4'-Hydroxyflavanone are not extensively reported. As a flavonoid with a molecular weight of 240.25 g/mol, the compound is expected to have moderate oral bioavailability. It is soluble in DMSO and other organic solvents. Storage: typically at room temperature or 4°C. Purity is typically >98%. The compound is a synthetic flavonoid analog with potential for metabolic research. Further PK studies would be required for comprehensive characterization.
|
| Toxicity/Toxicokinetics |
4'-Hydroxyflavanone is supplied for research use only and is not intended for human administration. Toxicity data are limited, but as a flavonoid compound, it is expected to have relatively low toxicity. Antioxidant and anti-inflammatory properties suggest potential beneficial effects, but high doses may have adverse effects. Standard laboratory safety precautions should be followed. The compound should be stored appropriately. No specific toxicological studies have been published.
|
| References | |
| Additional Infomation |
4'-Hydroxyflavanone is a monohydroxyflavanone belonging to the 4'-hydroxyflavanone family. It has been reported that 4'-hydroxyflavanone is present in carnations (Dianthus caryophyllus), and relevant data are available for reference.
4'-Hydroxyflavanone (CAS 6515-37-3) is a research compound supplied for laboratory use only. It is not an approved drug and has no clinical trial or marketing authorization status. The compound is a synthetic flavonoid analog that inhibits SREBP maturation and lipid synthesis. It has antioxidant, anti-inflammatory, and anticancer properties. Purity is typically >98%. The compound appears as a solid and should be stored at room temperature or 4°C. |
| Molecular Formula |
C15H12O3
|
|---|---|
| Molecular Weight |
240.2540
|
| Exact Mass |
240.078
|
| CAS # |
6515-37-3
|
| PubChem CID |
165506
|
| Appearance |
Off-white to light yellow solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
447.5±45.0 °C at 760 mmHg
|
| Melting Point |
182°C
|
| Flash Point |
174.0±22.2 °C
|
| Vapour Pressure |
0.0±1.1 mmHg at 25°C
|
| Index of Refraction |
1.632
|
| LogP |
2.88
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
18
|
| Complexity |
307
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
ZLHVIYHWWQYJID-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C15H12O3/c16-11-7-5-10(6-8-11)15-9-13(17)12-3-1-2-4-14(12)18-15/h1-8,15-16H,9H2
|
| Chemical Name |
2-(4-hydroxyphenyl)-2,3-dihydrochromen-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~416.23 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (10.41 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (10.41 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (10.41 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.1623 mL | 20.8117 mL | 41.6233 mL | |
| 5 mM | 0.8325 mL | 4.1623 mL | 8.3247 mL | |
| 10 mM | 0.4162 mL | 2.0812 mL | 4.1623 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
